无对比剂合成MRI与表观扩散系数影像组学分析用于早期预测乳腺癌新辅助化疗反应
前瞻性纳入267例接受新辅助化疗的乳腺癌患者,按时间顺序分为训练组145例、验证组62例和测试组60例,比较无对比剂合成MRI(SyMRI)与ADC的影像组学特征在早期预测化疗反应中的价值。delta-SyT2与1st-ADC联合模型AUC为0.809/0.809/0.810(训练/验证/测试),加入受体状态后非对比剂临床-影像组学模型AUC最高达0.916/0.914/0.850。结论认为多参数SyMRI与ADC作为非对比剂序列有潜力在影像组学分析中早期预测新辅助化疗反应。
要点
- SyMRI衍生的delta影像组学模型优于对应的pre-和1st-模型。
- 1st-ADC影像组学模型优于对应的pre-和delta-模型。
- delta-SyT2与1st-ADC联合模型AUC为0.809/0.809/0.810,较单独模型高但无显著差异。
核心结论
- 多参数SyMRI与ADC作为非对比剂序列,在影像组学分析中有潜力早期预测乳腺癌新辅助化疗反应。
研究设计与样本
- 前瞻性研究,纳入267例接受新辅助化疗后手术的乳腺癌患者,按时间顺序分为训练组145例、验证组62例和测试组60例;所有患者在新辅助化疗前和第一周期后接受含SyMRI与DWI的乳腺MRI检查。
诊断标准与关键数值
- 从DWI-ADC和SyMRI定量图(SyT1/SyT2/SyPD)提取pre-和1st-影像组学特征并计算delta特征,采用SVM-RFE筛选特征并建模;delta-SyT2与1st-ADC联合模型AUC(训练/验证/测试)为0.809(95%CI: 0.730-0.888)/0.809(95%CI: 0.691-0.927)/0.810(95%CI: 0.687-0.933);加入受体状态后非对比剂临床-影像组学模型AUC为0.916(95%CI: 0.869-0.963)/0.914(95%CI: 0.838-0.991)/0.850(95%CI: 0.747-0.954)。
临床应用与阅片要点
- SyMRI衍生的delta影像组学模型优于对应的pre-和1st-模型,1st-ADC模型优于对应的pre-和delta-模型,两者联合及加入受体状态可提升预测性能。
局限性
- delta-SyT2与1st-ADC联合模型AUC较单独模型高但无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the value of the radiomics features extracted from the contrast-free synthetic MRI (SyMRI) and apparent diffusion coefficient (ADC) in the early prediction of treatment response to neoadjuvant chemotherapy (NAC) in breast cancer.
METHODS: 267 breast cancer patients who received neoadjuvant chemotherapy (NAC) before surgery were prospectively enrolled and divided into the training cohort (n = 145), validation cohort (n = 62) and test cohort (n = 60) in a chronological order. All patients underwent breast MRI with SyMRI and Diffusion-weighted imaging (DWI) before (pre-) and after the first cycle (1st-) of NAC. Pre- and 1st- radiomics features were extracted from DWI-ADC and SyMRI quantitative maps (SyT1/SyT2/SyPD), and their changes (delta-radiomics features) were calculated. The support vector machine with recursive feature elimination (SVM-RFE) was used to select features and build models using separate and combined maps. The model performance was assessed by area under receiver operating characteristic curve (AUC) and compared by Delong test.
RESULTS: SyMRI-derived delta-radiomics models outperformed the corresponding pre- and 1st-models. The 1st-ADC radiomics model outperformed the corresponding pre- and delta-models. The delta-SyT2 and 1st-ADC achieved the optimal combination with a higher but no significant AUC (training/validation/test) of 0.809(95% CI: 0.730-0.888)/0.809(95% CI: 0.691-0.927)/0.810 (95% CI: 0.687-0.933) compared with the separate models. After adding receptor status, the noncontrast clinical-radiomics achieved the highest AUC of 0.916(95% CI: 0.869-0.963)/0.914(95% CI: 0.838-0.991)/0.850(95% CI: 0.747-0.954) compared with the clinical and radiomics models.
CONCLUSIONS: Multiparametric SyMRI and ADC, as noncontrast sequences, have the potential to early predict NAC response in radiomics analysis, thus reducing the need for repeated contrast agent injections during treatment.
引用
- Zhang Y, Zhao R, Du S, et al. Radiomics analysis of contrast-free synthetic MRI and apparent diffusion coefficient for early predicting neoadjuvant chemotherapy response in breast cancer. Eur J Radiol. 2025. PMID: 40829300. doi:10.1016/j.ejrad.2025.112344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。